Hero Mask
Hero Mask

NEWS

Discover how Chroma Medicine is expanding our impact.

PRESS RELEASE
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
Cambridge, MA, September 20, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB) comprising renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley Bernstein, M.D., Ph.D., Paula Cannon, Ph.D., Howard Chang, M.D., Ph.D., and Ahmad (Mo) Khalil, Ph.D. The SAB members will provide key input to Chroma as the company advances its programs addressing a wide range of diseases. “Each of these distinguished experts will be instrumental as we unlock the potential of epigenetic editing therapeutics,” said Catherine Stehman-Breen, M.D., Chief…
PRESS RELEASE
Chroma Medicine Strengthens Leadership with Addition of George Golumbeski to Board of Directors and John Maraganore as Strategic Advisor
Cambridge, MA, May 24, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering epigenetic editing therapeutics, today announced the appointment of George Golumbeski, Ph.D., former Executive Vice President of Business Development at Celgene, as an Independent Director and John Maraganore, Ph.D., former CEO of Alnylam, as a Strategic Advisor. “We are thrilled to welcome George and John to the Chroma team. They are both remarkable pioneers in building leading biotechnology companies that have brought important innovative treatments to patients,” said Catherine Stehman-Breen, M.D., Chief Executive Officer of Chroma. “Their deep experience will be invaluable to Chroma and the…
PRESS RELEASE
Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing
Cambridge, MA, November 17, 2021 – Chroma Medicine, Inc., (Chroma) a new genomic medicine company pioneering epigenetic editing, launched today with $125M in financing. Atlas Venture and Newpath Partners seeded the company with participation from Sofinnova Partners. The Series A was led by Cormorant Asset Management with participation by Casdin Capital, Janus Henderson Investors, Omega Funds, funds and accounts advised by T. Rowe Price Associates, Inc., and Wellington Management in addition to all seed investors.The financing will support continued development of the company’s epigenetic editing platform and advancement of its pipeline of targeted therapeutics. Chroma has assembled a highly experienced…